Business Context and Reporting Period
Company: The Joint Corp. (JYNT)
Filing Type: Form 8-K (Current Report)
Date of Report: July 24, 2025
Reporting Period: The filing addresses material errors in previously issued financial statements for the year ended December 31, 2024, and the quarter ended March 31, 2025.
Key Financial Metrics and Adjustments
The filing details a restatement of financial results due to a misapplication of accounting guidance regarding the valuation of assets held for sale within discontinued operations. The filing does not provide current period revenue, profit, or cash flow figures, but outlines the following preliminary estimated impacts of the correction:
- Year Ended Dec 31, 2024:
- Reduction of previously reported loss from discontinued operations (pre-tax): ~$2.2 million.
- Decrease in net loss: ~$2.2 million.
- Increase in carrying value of assets held for sale: ~$2.2 million.
- Quarter Ended Mar 31, 2025:
- Increase of previously reported income from discontinued operations (pre-tax): ~$0.5 million.
- Increase in net income: ~$0.5 million.
- Cumulative increase in carrying value of assets held for sale: ~$2.7 million.
- Unaffected Metrics: The adjustments are not expected to impact Adjusted EBITDA, cash, cash equivalents, or restricted cash for the respective periods.
Material Changes and Restatement Details
The company concluded that its previously issued audited financial statements (Form 10-K for 2024) and unaudited interim statements (Form 10-Q for Q1 2025) contained material errors. The error stemmed from an incorrect valuation methodology for the impairment of company-owned or managed clinics classified as held for sale. Consequently, investors are advised not to rely on the previously issued financial statements or related earnings releases.
Outlook, Risks, and Management Commentary
Management Actions:
- The Audit Committee and Board of Directors have ratified the decision to restate the financial statements.
- The company intends to file amended reports (10-K/A and 10-Q/A) as soon as practical.
- Management expects the errors to result in a material weakness in internal control over financial reporting and ineffective disclosure controls for the applicable periods.
- Internal Controls: Potential failure to remediate material weaknesses could impact the ability to accurately report results and maintain investor confidence.
- Operational Risks: Nationwide labor shortages affecting staffing, inflation increasing costs, and potential failure to profitably operate or refranchise clinics.
- Market Risks: Short-selling strategies and negative online opinions could drive down stock price and lead to class action lawsuits.
Investor Verification Checklist
- Verify the filing of the amended Form 10-K/A and Form 10-Q/A to obtain the restated financial figures.
- Review the updated assessment of internal controls over financial reporting and the plan to remediate the identified material weakness.
- Confirm the final impact of the restatement on the carrying value of assets held for sale and net income/loss once the restatement is complete.
- Monitor for any class action lawsuits or regulatory inquiries related to the restatement and the effectiveness of disclosure controls.